Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Oct 24;15(11):2421–2429. doi: 10.1111/j.1582-4934.2010.01229.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

PMC Copyright notice

Fig 3 — IFN-β effects on cathepsins and cystatins expression in PBLs and sera from MS patients in remission. (A) Expression levels of cathepsins and cystatins following a 3–6 month period of IFN-β treatment and relative to pre-treatment levels, quantified by 2^−ΔΔC_T values; n= 16. (B) Cathepsin S serum protein levels before and following a 3–6 month period of IFN-β treatment were analysed by ELISA (n= 27). (C) Ratios between the serum levels of the proteases and the cystatin C inhibitor. Horizontal bars: median of fold changes of during treatment relative to pre-treatment ratios.

Fig 3 — IFN-β effects on cathepsins and cystatins expression in PBLs and sera from MS patients in remission. (A) Expression levels of cathepsins and cystatins following a 3–6 month period of IFN-β treatment and relative to pre-treatment levels, quantified by 2^−ΔΔC_T values; n= 16. (B) Cathepsin S serum protein levels before and following a 3–6 month period of IFN-β treatment were analysed by ELISA (n= 27). (C) Ratios between the serum levels of the proteases and the cystatin C inhibitor. Horizontal bars: median of fold changes of during treatment relative to pre-treatment ratios.